Cell-Based Assays Market Size

Global Cell-Based Assays Market size was valued at USD 17.2 billion in 2023 and is poised to grow from USD 18.46 billion in 2024 to USD 32.43 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032). 

The global research landscape, including major clinical trials and drug discovery efforts, was profoundly disrupted by the COVID-19 pandemic. To address research backlogs, researchers worldwide swiftly adopted efficient and time-sensitive methodologies. Moreover, a multitude of cell-based assays were specifically developed for detecting COVID-19 infections, with several tests gaining FDA approval for global emergency use. An illustrative example is the T-Detect COVID-19 routine T-cell test (by Adaptive Biotechnologies), which obtained Emergency Use Authorization from the U.S. FDA in May 2021. This innovative Next-Generation Sequencing (NGS)-based test facilitates the identification of T-cells recognizing SARS-CoV-2 antigens, confirming recent infections.

Cell-based drug screening assays have played an integral role in drug discovery research, enabling the meticulous selection of promising drug candidates from vast compound libraries. The scope of these assays spans a diverse spectrum, influenced by multifaceted considerations in various drug development trajectories. Anticipated advancements in drug discovery hold promise for fostering an environment conducive to industry growth. A compelling instance is the groundbreaking development unveiled in September 2022 by Fraunhofer Institute researchers—Proxidrugs—a therapeutic prospect harnessing cell-based waste disposal systems to address conditions like infections, cancer, and Alzheimer's disease. This underscores the versatility of cell-based assays in driving scientific innovation and therapeutic evolution.

The market is currently poised for robust growth due to factors such as surging demand for drug discovery, an escalated requirement for biotechnology research, and the mounting incidence of infectious diseases, cancer, autoimmune disorders, and genetic anomalies. Cell-based assays play a pivotal role in the drug discovery process, not only for validating potential drug candidates but also for lead profiling, analyzing cellular signaling, and assessing toxicity. A prime example is The Annexin V-Cy3 apoptosis detection kit (by Cell Biologics), which leverages fluorescence to detect apoptosis—a testament to the diverse applications of these assays in comprehensive cellular analysis.

US Cell-Based Assays Market is poised to grow at a sustainable CAGR for the next forecast year.